期刊文献+

成人淋巴母细胞淋巴瘤合并急性髓细胞白血病1例并文献复习 被引量:2

Concurrent acute myeloid leukemia and T lymphoblastic lymphoma:a case report and review of literature
原文传递
导出
摘要 成人淋巴母细胞淋巴瘤(LBL)与急性髓细胞白血病(AML)均是血液系统高度恶性疾病,临床进展迅速,预后较差〔1〕。LBL和AML由于肿瘤细胞系别来源不同,临床大多单独起病,罕见两种疾病同时发生于同一患者。 Lymphoblastic lymphoma(LBL)and acute myeloid leukemia(AML)are highly aggressive hematologic malignancies,but concurrent LBL and AML in the same patient is rare.Here,we reported a case of 24 years old male patient with diagnosis of LBL in lymph node and AML in bone marrow respectively.The patient was treated with idarubicin and cytarabine(IA regimen)as induction therapy,but only partial remission was reached,and treatment was switched to intensive regimen(FLAG+aclacinomycin).After one cycle of salvage therapy with FLAG+aclacinomycin,complete remission was attained and allogeneic stem cell transplantation was recommended as consolidation therapy.
出处 《临床血液学杂志》 CAS 2015年第1期67-69,共3页 Journal of Clinical Hematology
基金 国家自然科学基金青年基金项目(No:81200360) 江苏省自然科学基金青年基金项目(No:BK2012484)
关键词 淋巴母细胞淋巴瘤 急性髓细胞白血病 FLAG方案 lymphoblastic lymphoma acute myeloid leukemia FLAG regimen
  • 相关文献

参考文献8

二级参考文献17

  • 1杨文博,孔佩艳,刘红,彭贤贵,张哉根.非霍奇金淋巴瘤合并急性髓系白血病M_(2a)型二例[J].中华血液学杂志,2004,25(10):595-595. 被引量:3
  • 2张青,韩明哲,秘营昌,肖志坚,邱录贵,冯四洲,杨仁池,李睿,卞寿庚,王建祥.FLAG方案治疗难治、复发性急性髓系白血病的临床研究[J].中华血液学杂志,2005,26(11):682-684. 被引量:18
  • 3Jackson G, Taylor P, Smith GM, et al. A multicentre, open, noncomparative phase Ⅱ study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukemia and de novo refractory anemia with excess blasts in transformation. Br J Haematol,2001 ; 112 : 127 - 137
  • 4Higashi Y, Turzanski J, Pallis M, et al. Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic lenkaemia. Br J Haematol, 2000 ; 111:565 - 569
  • 5Fleischhack G, Graf N, Hasan C, et al. IDA-FLAG ( idarubicin, fludarabine, high dosage cytarabine and G-CSF )-an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study. Klin Padiatr, 1996 ;208:229 - 235
  • 6Yalman N, Sarper N, Devecioglu O, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia. Turk J Pediatr, 2000 ;42 : 198 - 204
  • 7Yavuz S, Paydas S, Disel U, et al. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a singlecenter experience. Am J Ther, 2006 ;13:389 -393
  • 8Hashrni KU, Khan B, Ahmed P, et al. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study. J Pak Med Assoc, 2005;55:234 -238
  • 9Montesinos P, Rubia Jdl, Orti G, et al. FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk acute myeloid leukemia and myelodysplastic syndromes. Blood (ASH Annual Meeting Abstracts ), 2007;110:2866
  • 10Reiter A,Schrappe M,Ludwig WD,et al.Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma:a BFM group report.Blood,2000,95:416-421.

共引文献48

同被引文献7

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部